Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

67.63 +1.70 (+2.58%)
Streaming Delayed Price Updated: 11:25 AM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 28, 2022 ↗
Companies Reporting Before The Bell • Pinduoduo (NASDAQ:PDD) is projected to report quarterly earnings at $0.65 per share on revenue of $4.31 billion. 
Via Benzinga
Earnings Preview For Arrowhead Pharmaceuticals ↗
 
Via Benzinga
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
News headline image
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 ↗
Upgrades 
Via Benzinga
News headline image
What 7 Analyst Ratings Have To Say About Arrowhead Pharmaceuticals ↗
  Analysts have provided the following ratings for Arrowhead Pharmaceuticals (NASDAQ:ARWR) within the last quarter: 
Via Benzinga
News headline image
Arrowhead Pharmaceuticals: Q3 Earnings Insights ↗
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported its Q3 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming June 2022 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Where Arrowhead Pharmaceuticals Stands With Analysts ↗
Within the last quarter, Arrowhead Pharmaceuticals (NASDAQ:ARWR) has observed the following analyst ratings: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Arrowhead Pharmaceuticals: Q2 Earnings Insights ↗
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported its Q2 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Evers and Announces Receipt of Incentives
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Week In Review: I-Mab Files For Hong Kong SPAC IPO To Acquire Life Science Company ↗
I-Mab and one of its investors, VMS, have filed for a Hong Kong IPO of a SPAC that will raise funds to acquire a life science company. Also, RVAC Medicines completed a Series B funding that brings... 
Via Talk Markets
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.